Estrella Immunopharma, Inc. (ESLA)

NASDAQ: ESLA · USD

$0.85

-0.08 (-8.8%)· Recorded snapshot

Market cap	37M
Net income (ttm)	-10M
EPS (ttm)	-$0.25
Shares out	43.5M
Volume	478,125
Beta	0.93

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -10M
EPS (ttm): -$0.25
Market cap: 37M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ESLA indicators

Market & fundamental data

Available fields

160

Groups with data

Currency

USD

Showing 160 of 160 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001844417
Company name	Estrella Immunopharma, Inc.
Country	United States
Country code	US
CUSIP number	297584104
Earnings date	2026-11-11
Earnings time	amc
Enterprise value	$36.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2021
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US2975841048
Last 10-K release date	2026-03-18
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$37M
Market cap category	Nano-Cap
Next earnings date	2026-11-11
Options	No
Price	$0.85
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ESLA
U.S. state	California
Website	https://www.estrellabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-29.45%
FCF / EV yield	-25.79%
FCF yield	-25.68%
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
ROA	-251.86%
ROCE	130.29%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	0
Net income growth quarters	1
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-9.7M
EPS	$-0.25
FCF per share	$-0.22
Financing cash flow	$8.2M
Free cash flow	$-9.4M
Free cash flow minus SBC	$-10M
Income taxes	$-25
Net cash flow	$-1.2M
Net income	$-10M
Operating cash flow minus SBC	$-10M
Operating income	$-9.7M
Stock-based compensation	$592,793

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-0.17
Long-term assets	$0
Long-term liabilities	$0
Net cash (debt)	$146,670
Net cash / market cap	0.4%
Net cash growth	-88.83%
Piotroski F-Score	2
Shareholders' equity	$-7.4M
Tangible book value	$-7.4M
Tangible book value per share	$-0.17
Total assets	$1.8M
Total cash	$146,670
Total debt	$0
Total liabilities	$9.3M
WACC	9.37%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$1.8M
Current liabilities	$9.3M
Current ratio	0.2
Net working capital	$-7.6M
Quick ratio	0.02
Working capital	$-7.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-10.44%
Dividend yield	0%
Shareholder yield	-10.44%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$0.94
1D price change	-8.85%
1M price change	76.67%
1M total return	76.67%
1W price change	54.51%
1W total return	54.51%
1Y price change	-62.73%
1Y return CAGR	-62.75%
1Y total return	-62.73%
20-day SMA	$0.54
200-day SMA	$0.99
3M price change	9.68%
3M total return	9.68%
3Y price change	-48.81%
3Y return CAGR	-20%
3Y total return	-48.81%
50-day SMA	$0.59
50-day SMA vs 200-day SMA	50under200
52-week high	$3.15
52-week high date	2025-11-04
52-week low	$0.24
52-week low date	2026-10-19
5Y price change	-91.42%
5Y return CAGR	-38.82%
5Y total return	-91.42%
6M price change	-49.42%
6M total return	-49.42%
All-time high	$33.00
All-time high date	2023-09-01
All-time low	$0.24
All-time low date	2026-10-19
Average true range (ATR)	$0.14
Average volume	5.6M
Beta (1Y)	2.03
Beta (2Y)	1.45
Beta (5Y)	0.93
Change from 52-week high	-73.02%
Change from 52-week low	254.08%
Change from all-time high	-97.42%
Change from all-time low	254.08%
Change from open	-5.59%
Day's gap	-3.45%
Dollar volume	$406,311
High price	$0.94
Low price	$0.77
Monthly RSI	40.47
Open price	$0.90
Position in 52-week range	47.47%
Premarket change	-3.45%
Premarket close	$0.93
Premarket price	$0.90
Premarket volume	3.9K
Previous close	$0.93
Price vs 150-day SMA	-10%
Price vs 20-day SMA	58.43%
Price vs 200-day SMA	-14.32%
Price vs 50-day SMA	45.09%
Relative volume	0.09
RSI	64.22
Sharpe ratio	-0.07
Sharpe ratio (3Y)	0.4
Sortino ratio	-0.08
Sortino ratio (3Y)	0.73
Volume	478.1K
Weekly RSI	50.21
YTD price change	-45.53%
YTD total return	-45.53%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	38.2M
Float percentage	87.85%
Shares change (QoQ)	2.08%
Shares change (YoY)	10.44%
Shares held by insiders	2.31%
Shares held by institutions	1.89%
Shares outstanding	43.5M
Short % of float	0.56%
Short % of shares	0.49%
Short ratio	5.2 days

Deeper analysis on ESLA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ESLA report

Is a complete ESLA research report available?

No complete published report is available for Estrella Immunopharma, Inc. (ESLA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Estrella Immunopharma, Inc. (ESLA)

Price

Financial snapshot

Fair-value bridge

Latest news · ESLA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ESLA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ESLA

Frequently asked questions